Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis

Medical treatment of hypercalcaemia

(2014) Polyzois Makras et al.   Hormones-International Journal of Endocrinology and Metabolism

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

(2012) Athanasios Anastasilakis   Therapeutics and Clinical Risk Management

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?

(2010) Dominique D. Pierroz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

(2010) Ego Seeman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

(2010) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

(2010) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE